Non-small cell lung cancer (NSCLC) is a type of lung cancer affecting around 85% of all lung cancer diagnoses. Epidermal Growth Factor Receptor – Tyrosine Kinase Inhibitor (EGFR-TKI) is an effective therapeutic approach for NSCLC patients. However, the use of first- and second-generation EGFR-TKI therapy causes EGFR mutations and eventually leads to resistance. Prevention of resistance due to TKI therapy is needed through early detection of EGFR mutation. Biopsy is the common diagnostic method in NSCLC; however, this technique is invasive to NSCLC patients. In addition, the biopsy is unable to describe the type of mutation because of the tiny sample used while the cancer is heterogeneous. The use of molecular imaging techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) is a guaranteed option because it is non-invasive and is able to determine mutation status in detail. Thus, this study aims to review the radiotracer that has been developed to detect EGFR mutations, especially in the L858R/T790M EGFR double mutations. Our results showed that some radiotracers such as [¹⁸F]FEWZ, [¹²⁵I]ICO1686, and [⁷⁷Br]BrCO1686 have high in vitro selectivity for the double mutations EGFR L858R/T790M. However, these compounds showed insufficient in vivo accumulation toward EGFR L858R/T790M. Therefore, further study to find out new molecular probe for EGFR double mutations is needed.